Counteracting IDO1 activities has resulted in the reactivation of anticancer immune responses in animal studies with tumour models [105], suggesting that blockage of IDO1 may also represent a promising therapeutic candidate for HRPC. The gene discussed is IDO1; the disease is neoplasm.